CytoSorbents (CTSO) Q4 2025 earnings review
Core Growth Stalls Amid Delayed Breakeven and Regulatory Resets
CytoSorbents ended 2025 with highly mixed results. While Q4 gross margins expanded nicely to 74%, top-line growth decelerated to just 1% year-over-year (and shrank 8% on a constant currency basis). The core issue remains a struggling German direct sales segment, which fell 10% for the full year despite ongoing restructuring efforts. Critically, management quietly pushed back its timeline for achieving cash flow breakeven from Q1 2026 to the second half of 2026, putting further pressure on a balance sheet that ended the year with just $7.8M in cash. Meanwhile, the crucial DrugSorb-ATR product remains in regulatory limbo as the company abandons its FDA appeal in favor of a brand-new De Novo submission.
🐂 Bull Case
Outside of Germany, the core business is performing well. Full-year direct sales outside Germany grew 13.0%, and distributor sales increased 11.4%. Together, these segments now make up 68% of total revenue.
Q4 gross margins jumped to 74% (from 70% last year). With recent headcount reductions (-10%) and production efficiencies, the company is demonstrating operating leverage on its unit economics.
🐻 Bear Case
Germany—historically the company's anchor market—contracted 10% in 2025. Restructuring efforts have yet to translate into sustained top-line recovery.
Cash dropped to $7.8M despite drawing an additional $2.5M in debt in November. With cash flow breakeven delayed until H2 2026, the company faces a narrow margin for error without further dilution.
⚖️ Verdict: 🔴
Bearish. Decelerating revenue growth, delayed profitability targets, and the necessity of a completely new FDA submission for DrugSorb-ATR outweigh the positives of improved gross margins and ex-Germany sales growth.
Key Themes
Breakeven Goalposts Moved
In Q3 2025, management explicitly stated they expected the cost reduction program to enable operating cash flow breakeven 'beginning in Q1 2026.' In this Q4 release, that guidance has been quietly revised to 'the second half of 2026.' This reversal implies heavier expected cash burn in the first half of the year than previously communicated, raising alarms given the dwindling $7.8M cash balance.
DrugSorb-ATR Regulatory Reset
After the FDA upheld its denial of the DrugSorb-ATR De Novo request in August, the company elected to stop the appeals process entirely. They are now pivoting to submit a new De Novo application utilizing new real-world data from the STAR Registry. While they held a pre-submission meeting in January 2026, the timeline for filing and approval is entirely reset, further delaying access to the estimated $300M+ U.S. market.
Ex-Germany Sales Show Underlying Demand
While Germany struggles, the rest of the world is adopting the technology. Full-year distributor sales hit $16.5M (+11.4%), and direct sales outside Germany reached $8.6M (+13%). This geographic diversification reduces reliance on the stagnant German hospital network.
German Sales Turnaround Remains Elusive
Germany sales dropped 10% to $11.8M for the full year. While management cited 'incremental improvement' expected across 2026 due to better customer targeting and sales resource allocation, this segment has been a persistent drag on the company's overall growth trajectory.
Expanding Real-World Clinical Evidence
The company crossed 300,000 cumulative treatments globally. Crucially, they continue to publish peer-reviewed evidence across multiple indications, including a Journal of Clinical Medicine meta-analysis showing a halving of 28-30 day mortality in sepsis patients, and Liver International data showing CytoSorb increases the likelihood of transplant listing in Acute Liver Failure.
Other KPIs
Accelerating. Up from 70% in Q4 2024. A bright spot in the report, indicating that while revenue growth is sluggish, the unit economics of the physical cartridges remain highly favorable, aided by increased inventory buffers and production efficiencies.
Decelerating. Down from $9.1 million at the end of Q3, despite receiving $2.5 million from an amended credit facility in November. This indicates an ongoing structural cash burn that requires immediate stemming before the H2 2026 breakeven target.
Reversing. Wider than the $3.7 million loss in Q4 2024. This was primarily driven by a $0.5 million restructuring charge tied to the Q4 workforce and cost reduction program (a 10% headcount reduction).
Guidance
Decelerating/Delayed. Previously guided for Q1 2026. This delay requires close monitoring, as achieving this target is existential for the company without executing further dilutive equity raises or taking on more debt.
Key Questions
Breakeven Timeline Shift
The cash flow breakeven target shifted from Q1 2026 to the second half of 2026. What specific operational headwinds or revenue assumptions forced this delay?
Liquidity Runway
With $7.8 million in cash and cash flow breakeven not expected until H2 2026, does management believe current liquidity is sufficient to bridge the gap without another capital raise?
DrugSorb-ATR Regulatory Strategy
By abandoning the appeal and submitting a new De Novo application for DrugSorb-ATR, what is the realistic timeline for U.S. commercialization, and is an additional clinical trial entirely off the table?
German Market Dynamics
Germany sales fell 10% in 2025. How much of this decline was due to internal sales force disruption versus external macroeconomic/hospital budgeting pressures?